PA
AQST icon

Profund Advisors’s Aquestive Therapeutics AQST Stock Holding History

Profund Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
32,739
+7,355
+29% +$31K ﹤0.01% 1126
2026
Q1 		$105K Sell
25,384
-3,787
-13% -$15.4K ﹤0.01% 1068
2025
Q4 		$188K Buy
+29,171
New +$182K 0.01% 1184

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Profund Advisors's AQST Position: Q2 2026 in Review

Profund Advisors increased its Aquestive Therapeutics (AQST) stake by 29% in Q2 2026, buying an estimated $31K and bringing the position to 32,739 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Profund Advisors first reported a position in AQST in Q4 2025 and has held it in 3 quarters since. The position peaked at $188K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Profund Advisors held 32,739 shares of Aquestive Therapeutics worth $136K as of Q2 2026.
  • Profund Advisors bought 7,355 Aquestive Therapeutics shares in Q2 2026, an estimated $31K.
  • Aquestive Therapeutics made up ﹤0.01% of Profund Advisors's portfolio in Q2 2026, its #1126 holding.
  • Profund Advisors first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Profund Advisors's Aquestive Therapeutics position peaked at $188K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.